IMMU-132 in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy

• Status: Recruiting
• Trial end date: 2024-06-01

Summary

This study will investigate the safety and efficacy of IMMU-132 in patients with metastatic castration-resistant prostate cancer progressing on abiraterone or enzalutamide.

• Phase: Phase 2

Details

• Lead Sponsor: University of Wisconsin, Madison
• Collaborators: Gilead Sciences; Immunomedics, Inc.; National Cancer Institute (NCI)
• Treatments: Camptothecin; Immunoconjugates